Physician profile
Amber Fields
NPI 1639629835
$4,093.42
in general payments reported to CMS, 2019-2025
33 companies · $587 in 2025
The $587 reported for 2025 was more than what 79% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $1,111 · 2023: $714 · 2024: $918 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Education: $85.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.73 |
| Education | $85.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $749.98 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $539.20 | 2021-2025 | |
| Janssen Biotech, INC. | $351.33 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $307.02 | 2021-2025 | Entyvio, Eohilia |
| Otsuka America Pharmaceutical, INC. | $232.42 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $222.54 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $194.75 | 2022-2025 | |
| Daiichi Sankyo INC. | $162.96 | 2021-2025 | Injectafer |
| Travere Therapeutics, INC. | $148.79 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $143.25 | 2022-2024 | Linzess |
| Opko Pharmaceuticals, LLC | $142.09 | 2021-2024 | Rayaldee |
| Ardelyx, INC. | $106.92 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $95.82 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.02 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $73.72 | 2024-2025 | Zenpep |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $70.40 | 2024 | Voquezna |
| Amgen INC. | $68.00 | 2021-2023 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.22 | 2024-2025 | Jardiance |
| Gilead Sciences, INC. | $52.84 | 2021 | |
| Aurinia Pharma U.S., INC. | $40.35 | 2021 | |
| Vifor Pharma, INC. | $36.32 | 2021-2025 | Veltassa |
| Akebia Therapeutics INC | $30.32 | 2021 | |
| Glaxosmithkline, LLC. | $29.85 | 2021-2022 | |
| Celltrion USA INC. | $18.93 | 2025 | Vegzelma |
| Genzyme Corporation | $18.13 | 2024 | |
| Organon LLC | $17.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.17 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $15.51 | 2024 | Idacio |
| Evoke Pharma, INC. | $13.74 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.46 | 2021 | |
| Pfizer INC. | $12.20 | 2021 | |
| Sk Life Science, INC. | $11.30 | 2021 | |
| Dynavax Technologies Corporation | $7.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.